Evidence map›Paper›PMID 41450363›Full record

ArticleCureus2025

Beyond Traditional Risk Factors: Inflammation, Asymmetric Dimethylarginine, and N-Terminal pro-B-Type Natriuretic Peptide Predict Cardiovascular Risk in Chronic Kidney Disease.

Eneida Hoxha, Ledio Collaku, Somida Kuka, Saimir Seferi, Pandush Pojani, Xhesika Habilaj, Matilda Kambo, Elizana Zaimi Petrela, Anyla Bulo, Margarita Resuli

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eneida HoxhaDepartment of Internal Medicine, Clinic of Internal Medicine and Hypertension, University Hospital Center "Mother Teresa", Tirana, ALB.
Ledio CollakuDepartment of Internal Medicine, Clinic of Internal Medicine and Hypertension, University Hospital Center "Mother Teresa", Tirana, ALB.
Somida KukaDepartment of Internal Medicine, Clinic of Internal Medicine and Hypertension, University Hospital Center "Mother Teresa", Tirana, ALB.
Saimir SeferiDepartment of Nephrology Dialysis Transplatation, University Hospital Center "Mother Teresa", Tirana, ALB.
Pandush PojaniDepartment of Internal Medicine, Clinic of Internal Medicine and Hypertension, University Hospital Center "Mother Teresa", Tirana, ALB.
Xhesika HabilajDepartment of Internal Medicine, Clinic of Internal Medicine and Hypertension, University Hospital Center "Mother Teresa", Tirana, ALB.
Matilda KamboDepartment of Toxicology, University Hospital Center "Mother Teresa", Tirana, ALB.
Elizana Zaimi PetrelaDepartment of Public Health, Faculty of Medicine, University of Medicine, Tirana, ALB.
Anyla BuloDepartment of Laboratory Medicine, University Hospital Center "Mother Teresa", Tirana, ALB.
Margarita ResuliDepartment of Internal Medicine, Clinic of Internal Medicine and Hypertension, University Hospital Center "Mother Teresa", Tirana, ALB.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiovascular disease (CVD) is the leading cause of morbidity and mortality in chronic kidney disease (CKD). While traditional risk factors such as hypertension and diabetes are highly prevalent, they fail to fully explain the disproportionate cardiovascular (CV) burden. Non-traditional mechanisms, including inflammation, endothelial dysfunction, oxidative stress, and metabolic disturbances, are increasingly recognized.

objectiveThe objective of this study is to evaluate the prevalence and interplay of traditional and non-traditional CV risk factors in CKD, with a focus on biomarkers (IL-6, asymmetric dimethylarginine (ADMA), homocysteine, uric acid) and echocardiographic findings, and to determine their ability to predict N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.

methodsWe conducted a cross-sectional study of 100 CKD patients (stages I-V), of whom 21 (21%) were on hemodialysis. Demographic, clinical, laboratory, and echocardiographic data were collected. Biomarkers (IL-6 and homocysteine in all patients; ADMA in 52 patients) were measured. Correlation and multivariable regression analyses were used to identify predictors of NT-proBNP and echocardiographic abnormalities.

resultsThe cohort (60% male, mean BMI 27.4 kg/m²) showed a high prevalence of hypertension (83%) and diabetes (57%). Non-traditional biomarkers were frequently elevated: IL-6 (mean 23.5 pg/mL), homocysteine (mean 28.8 µmol/L), ADMA (mean 189.4 ng/mL), and uric acid (mean 8.5 mg/dL). Valvular calcifications were present in 52% of patients. NT-proBNP was markedly elevated (mean 10,912 pg/mL) and showed significant correlations with IL-6 (r = 0.211, p = 0.002) and ADMA (r = 0.334, p < 0.001). In multivariable regression analysis, both IL-6 (β = 0.207, p = 0.039) and ADMA (β = 0.385, p = 0.005) independently predicted NT-proBNP, with ADMA demonstrating the strongest effect. Hyperhomocysteinemia correlated with valvular calcifications, while uric acid was associated with hypertension and reduced eGFR.

conclusionBoth traditional and non-traditional factors contribute to the CV burden in CKD. Biomarkers of inflammation and endothelial dysfunction (IL-6, ADMA) are independent predictors of NT-proBNP and provide prognostic value beyond classical determinants. Incorporating these biomarkers into risk stratification models may improve prediction and guide innovative therapeutic strategies to reduce CV morbidity and mortality in CKD.

Indexed as

admacardio-renal-metabolic syndromecardiovascular riskchronic inflammationchronic kidney diseaseendothelial dysfunctionil-6nt-probnp

Identifiers

PMID41450363
PMCPMC12731469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.